Sign in
4

Changes in Ownership

Enliven Therapeutics, Inc. Filed Acc 0001209191-22-034382

Options or other derivatives

  • Director acquired 8,500 shares (grant or award)

From the SEC's structured data for this filing

Trades in this filing

Table II: Derivative

Insider Date Transaction Shares Price Value Exercise Expires Underlying Owned after D/I
MOTT DAVID M Director 2022-06-02 Grant or award · Stock Options (Right to Buy) +8,500 8,500 D: show line 1 in the form
Loading xslF345X03/doc4.xml…